Press Releases Detail:
Avitar Featured in Industry Week Web Exclusive Article
Highlights Importance of Random Oral Fluid-Based Drug Screening
to the U.S. Manufacturing Sector
March 08, 2007
CANTON, Mass., March 8 /PRNewswire/ -- Avitar, Inc. (OTCBB: - ) was featured in a web-exclusive article on IndustryWeek.com, the popular online home of IndustryWeek magazine. The article, titled "Workplace Drug Testing: A Necessary Procedure?" is authored by Avitar's VP of Marketing, Peter Cholakis. Industry Week is a highly regarded monthly magazine geared towards business leaders in the manufacturing sector. The article, listed first in the "Inside IndustryWeek.com" column, will be available at the following link through Monday, March 12:
"We are delighted to have an article by a top company executive featured in a publication with the stature of Industry Week," said Pete Phildius, Chairman & CEO of Avitar. "The fact that the publication has featured our VP of Marketing as an author and authority on the subject of manufacturing workplace drug abuse reflects the critical importance of the issue to the industry."
In the in-depth article, Mr. Cholakis writes, "According to the U.S. Department of Health and Human Services, 15% of manufacturing personnel, from CEOs to line workers, admitted to using illicit drugs in the past year." He continues, "With such high incidence rates, more manufacturing firms are considering random oral fluid (saliva)-based drug testing as a new standard of detection, an exam that is more cost-effective and convenient than traditional laboratory-based urinalysis."
IndustryWeek.com receives approximately 100,000 unique visitors per month, with an average of 250,000 page views monthly.
About Avitar, Inc.
Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen®, the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB®, an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at https://avitarinc.com.
This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.